Neuroendocrine Carcinoma Global Market Report 2025

The neuroendocrine carcinoma market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period was driven by the expansion of the imaging sector, a rising incidence of neuroendocrine tumors, increasing investments, government initiatives, and growing demand for treatments for neuroendocrine tumors.

The neuroendocrine carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period is expected to be driven by the rising incidence of cancer, an increasing rate of product approvals, greater adoption of advanced diagnostic imaging methods, the expansion of targeted therapies, and improved diagnosis and treatment options. Key trends include advancements in diagnostic and imaging technologies, the development of targeted treatment approaches, innovations in neuroendocrine tumor management, and continued progress in targeted therapies and immunotherapies.

The expansion of targeted therapies is expected to drive the growth of the neuroendocrine carcinoma market. Targeted therapies are designed to disrupt the molecular processes or genetic mutations responsible for disease progression, particularly in cancer. The increasing demand for targeted therapies is fueled by their precision in addressing specific genetic mutations, advancements in personalized medicine, and improved patient outcomes with fewer side effects. Neuroendocrine carcinoma research facilitates the development of targeted therapies that align with the tumor’s genetic and biochemical profiles, enhancing treatment accuracy and effectiveness. For instance, in July 2023, the American Society of Gene & Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in Phase II clinical trials increased by 5%, from 247 at the end of Q1 2023 to 260 by the end of Q2 2023. This growth underscores the increasing focus on targeted treatment strategies, driving the neuroendocrine carcinoma market.

Leading companies in the neuroendocrine carcinoma market are focusing on advancements in targeted radiopharmaceutical therapy to enhance treatment precision and improve patient outcomes. Targeted radiopharmaceutical therapy uses radioactive molecules that specifically deliver radiation to cancer cells while minimizing damage to healthy tissue. For example, in September 2024, Abdera Therapeutics Inc., a Canada-based biotechnology company, received an orphan drug designation from the FDA for ABD-147 for the treatment of neuroendocrine carcinoma. ABD-147 is designed to selectively target tumors expressing the DLL3 protein, which is commonly upregulated in aggressive neuroendocrine cancers such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). This designation provides significant benefits, including tax credits for clinical trials and potential market exclusivity, positioning ABD-147 as a promising treatment option in the field of oncology.

In February 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical company, acquired RayzeBio, Inc. for $4.1 billion. This acquisition aims to strengthen Bristol-Myers Squibb’s oncology pipeline, particularly in neuroendocrine tumors and other difficult-to-treat cancers, by leveraging RayzeBio’s expertise in targeted therapies and innovative drug development. RayzeBio Inc. is a US-based company specializing in the treatment of gastroenteropancreatic neuroendocrine tumors.

Major players in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.

North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroendocrine carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neuroendocrine carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Neuroendocrine carcinoma (NEC) is a rare and aggressive cancer that arises from neuroendocrine cells, which possess characteristics of both nerve cells and hormone-producing cells. It is diagnosed and treated to manage tumors that can develop in various organs, including the lungs, pancreas, and gastrointestinal tract, often requiring a combination of surgery, chemotherapy, and targeted therapies.

The primary types of neuroendocrine carcinoma include gastroenteropancreatic neuroendocrine tumors, carcinoid tumors, pheochromocytoma, and medullary thyroid carcinoma. Gastroenteropancreatic neuroendocrine tumors are rare malignancies that originate from neuroendocrine cells in the gastrointestinal tract or pancreas. Diagnosis involves various tools such as imaging, biopsy, and serology, while treatment options include chemotherapy, radiotherapy, surgery, and others. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, clinics, oncology centers, and ambulatory surgery centers.

The neuroendocrine carcinoma market research report is one of a series of new reports that provides neuroendocrine carcinoma market statistics, including the neuroendocrine carcinoma industry global market size, regional shares, competitors with the neuroendocrine carcinoma market share, detailed neuroendocrine carcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the neuroendocrine carcinoma industry. This neuroendocrine carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neuroendocrine carcinoma market consists of revenues earned by entities by providing services such as hormonal symptom management, long-term care plans, pain management, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroendocrine carcinoma market also consists of sales of products including somatostatin analogs, positron emission tomography (PET) scanners, needles and equipment, infusion pumps, and drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.